NasdaqGS:ALKSBiotechs
Assessing Alkermes (ALKS) Valuation After New Clinical And Real World Data On Key Psychiatry Drugs
Alkermes (NasdaqGS:ALKS) has drawn fresh attention after presenting new clinical and real world data on LYBALVI and ARISTADA at major psychiatry and health economics conferences, highlighting outcomes in schizophrenia, bipolar I disorder, and sleep medicine.
See our latest analysis for Alkermes.
These research updates land at a time when Alkermes’ share price has moved to US$39.94, with a 30 day share price return of 16.99% and a year to date share price return of 41.33%. The 1 year total...